210 related articles for article (PubMed ID: 34516331)
1. A critical review of incobotulinumtoxinA in the treatment of chronic sialorrhea in pediatric patients.
Jost WH; Steffen A; Berweck S
Expert Rev Neurother; 2021 Oct; 21(10):1059-1068. PubMed ID: 34516331
[TBL] [Abstract][Full Text] [Related]
2. Long-term incobotulinumtoxinA treatment for chronic sialorrhea: Efficacy and safety over 64 weeks.
Jost WH; Friedman A; Michel O; Oehlwein C; Slawek J; Bogucki A; Ochudlo S; Banach M; Pagan F; Flatau-Baqué B; Dorsch U; Csikós J; Blitzer A
Parkinsonism Relat Disord; 2020 Jan; 70():23-30. PubMed ID: 31794936
[TBL] [Abstract][Full Text] [Related]
3. SIAXI: Placebo-controlled, randomized, double-blind study of incobotulinumtoxinA for sialorrhea.
Jost WH; Friedman A; Michel O; Oehlwein C; Slawek J; Bogucki A; Ochudlo S; Banach M; Pagan F; Flatau-Baqué B; Csikós J; Cairney CJ; Blitzer A
Neurology; 2019 Apr; 92(17):e1982-e1991. PubMed ID: 30918101
[TBL] [Abstract][Full Text] [Related]
4. Randomized controlled trial comparing botulinum vs surgery for drooling in neurodisabilities.
Bekkers S; Delsing CP; Kok SE; van Hulst K; Erasmus CE; Scheffer ART; van den Hoogen FJA
Neurology; 2019 Mar; 92(11):e1195-e1204. PubMed ID: 30728311
[TBL] [Abstract][Full Text] [Related]
5. Effect of botulinum toxin in the treatment of drooling: a controlled clinical trial.
Jongerius PH; van den Hoogen FJ; van Limbeek J; Gabreëls FJ; van Hulst K; Rotteveel JJ
Pediatrics; 2004 Sep; 114(3):620-7. PubMed ID: 15342830
[TBL] [Abstract][Full Text] [Related]
6. Submandibular duct ligation after botulinum neurotoxin A treatment of drooling in children with cerebral palsy.
Bekkers S; Pruijn IMJ; Van Hulst K; Delsing CP; Erasmus CE; Scheffer ART; Van Den Hoogen FJA
Dev Med Child Neurol; 2020 Jul; 62(7):861-867. PubMed ID: 32149393
[TBL] [Abstract][Full Text] [Related]
7. Placebo-Controlled Clinical Trial of IncobotulinumtoxinA for Sialorrhea in Children: SIPEXI.
Berweck S; Bonikowski M; Kim H; Althaus M; Flatau-Baqué B; Mueller D; Banach MD
Neurology; 2021 Oct; 97(14):e1425-e1436. PubMed ID: 34341153
[TBL] [Abstract][Full Text] [Related]
8. Surgical management of chronic sialorrhea in pediatric patients: 10-year experience from one tertiary care institution.
Formeister EJ; Dahl JP; Rose AS
Int J Pediatr Otorhinolaryngol; 2014 Aug; 78(8):1387-92. PubMed ID: 24974144
[TBL] [Abstract][Full Text] [Related]
9. Factors in the Efficacy, Safety, and Impact on Quality of Life for Treatment of Drooling with Botulinum Toxin Type A in Patients with Cerebral Palsy.
Gonzalez-L MD; Martinez C; Bori Y Fortuny I; Suso-Vergara S
Am J Phys Med Rehabil; 2017 Feb; 96(2):68-76. PubMed ID: 28099276
[TBL] [Abstract][Full Text] [Related]
10. Onabotulinum Toxin A (BoNT-A) for Drooling in Children: A Systematic Review and Meta-Analysis.
Oad H; Maltezeanu A; da Silva SD; Daniel SJ
Laryngoscope; 2024 Jul; 134(7):3012-3017. PubMed ID: 38294288
[TBL] [Abstract][Full Text] [Related]
11. Intraparotid injection of botulinum toxin A as a treatment to control sialorrhea in children with cerebral palsy.
Savarese R; Diamond M; Elovic E; Millis SR
Am J Phys Med Rehabil; 2004 Apr; 83(4):304-11; quiz 312-4, 336. PubMed ID: 15024333
[TBL] [Abstract][Full Text] [Related]
12. Sialorrhea in patients with Parkinson's disease: safety and administration of botulinum neurotoxin.
Egevad G; Petkova VY; Vilholm OJ
J Parkinsons Dis; 2014; 4(3):321-6. PubMed ID: 24919823
[TBL] [Abstract][Full Text] [Related]
13. [Treatment of Sialorrhea with Botulinum Neurotoxin Type A - Consensus Practice Recommendations for Children and Adults].
Jost WH; Bäumer T; Bevot A; Birkmann U; Buhmann C; Grosheva M; Guntinas-Lichius O; Mlynczak U; Paus S; Pflug C; Schröder S; Steffen A; Wilken B; Berweck S
Fortschr Neurol Psychiatr; 2022 May; 90(5):212-221. PubMed ID: 35453158
[TBL] [Abstract][Full Text] [Related]
14. Does Botulinum neurotoxin type A treatment for sialorrhea change oral health?
Tiigimäe-Saar J; Taba P; Tamme T
Clin Oral Investig; 2017 Apr; 21(3):795-800. PubMed ID: 27114092
[TBL] [Abstract][Full Text] [Related]
15. Surgery versus botulinum neurotoxin A to reduce drooling and improve daily life for children with neurodevelopmental disabilities: a randomized controlled trial.
Bekkers S; Pruijn IMJ; van der Burg JJW; van Hulst K; Kok SE; Delsing CP; Scheffer ART; van den Hoogen FJA
Dev Med Child Neurol; 2021 Nov; 63(11):1351-1359. PubMed ID: 33997959
[TBL] [Abstract][Full Text] [Related]
16. Effects of salivary gland botulinum Toxin-A on drooling and respiratory morbidity in children with neurological dysfunction.
Gubbay A; Marie Blackmore A
Int J Pediatr Otorhinolaryngol; 2019 Sep; 124():124-128. PubMed ID: 31185343
[TBL] [Abstract][Full Text] [Related]
17. Pediatric Sialorrhea: Submandibular Duct Rerouting and Intraparotid Botulinum Toxin A Injection With Literature Review.
Calim OF; Hassouna HNH; Yildirim YS; Dogan R; Ozturan O
Ann Otol Rhinol Laryngol; 2019 Feb; 128(2):104-112. PubMed ID: 30371109
[TBL] [Abstract][Full Text] [Related]
18. Salivary gland botulinum toxin injections for drooling in children with cerebral palsy and neurodevelopmental disability: a systematic review.
Rodwell K; Edwards P; Ware RS; Boyd R
Dev Med Child Neurol; 2012 Nov; 54(11):977-87. PubMed ID: 22946706
[TBL] [Abstract][Full Text] [Related]
19. Use of botulinum neurotoxin A in uncontrolled salivation in children with cerebral palsy: a pilot study.
Tiigimäe-Saar J; Leibur E; Kolk A; Talvik I; Tamme T
Int J Oral Maxillofac Surg; 2012 Dec; 41(12):1540-5. PubMed ID: 23068112
[TBL] [Abstract][Full Text] [Related]
20. Botulinum neurotoxin type A in the interdisciplinary treatment of sialorrhea in adults and children-update and practice recommendations.
Jost WH; Bäumer T; Bevot A; Birkmann U; Buhmann C; Grosheva M; Guntinas-Lichius O; Laskawi R; Paus S; Pflug C; Schroeder AS; Spittau B; Steffen A; Wilken B; Winterholler M; Berweck S
Front Neurol; 2023; 14():1275807. PubMed ID: 38162447
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
